Analysis Of The Ifluencing Factors Of Severe Myelosuppression In Patients With Advanced Non-Small Cell Lung Cancer After Chemotherapy

Purpose:To explore the factors affecting severe myelosuppression,after first-line chemotherapy in patients with advanced non-small cell lung cancer,aiming to provide a reference for reducing the risk of myelosuppression in chemotherapy patients.Methods:A total of 111 patients with stage IIIB or stage IV non-small cell lung cancer who had no chance of surgery were selected from The First Affiliated Hospital of Nanchang University from May 2017 to December 2018.Chemotherapy with first-line TP regimen(paclitaxel plus cisplatin),GP regimen(gemcitabine plus cisplatin)or PC regimen(pemetrexed plus cisplatin)and indexing of the severity of myelosuppression(leukopenia,neutropenia,thrombocytopenia)using the indexing criteria for anti-tumor adverse drug reactions(WHO criteria)Degree of bone marrow suppression(0-II degree)and severe myelosuppression group(III-IV degree),and then use univariate analysis of age,gender,tumor type,tumor stage,presence or absence of smoking,presence or absence of medical complications,presence or absence of bone metastases,general condition(ECOG)scores,and nutritional status were associated with severe myelosuppression.Finally,univariate factors with statistical significance(P < 0.05)were used for multivariate logistic regression analysis.Results:Leukopenia,neutropenia,and thrombocytopenia with grade III or higher were 18%,21.6%,and 14.4%,respectively.The results of univariate analysis showed that age,gender,presence or absence of medical complications,ECOG score,bone metastasis,nutritional status and severe myelosuppression were associated(P<0.05).The results of multivariate logistic regression showed that age,ECOG score,bone metastasis,and nutritional status were the influencing factors of severe myelosuppression in patients with advanced non-small cell lung cancer(P<0.05).Conclusions:Aging,presence of bone metastases,high ECOG scores,and malnutrition are high risk factors for severe myelosuppression in patients with advanced non-small cell lung cancer chemotherapy.